Murine dendritic cells (DC) transduced to express the Type-1 transactivator T-bet (i.e. mDC.Tbet) and delivered intratumorally as a therapy are superior to control wild-type DC in slowing the growth of established subcutaneous MCA205 sarcomas in vivo. Optimal antitumor efficacy of mDC.Tbet-based gene therapy was dependent on host natural killer (NK) cells and CD8 þ T cells, and required mDC.Tbet expression of major histocompatibility complex class I molecules, but was independent of the capacity of the injected mDC.Tbet to produce proinflammatory cytokines (interleukin-12 family members or interferon-g) or to migrate to tumor-draining lymph nodes based on CCR7 ligand chemokine recruitment. Conditional (CD11c-DTR) or genetic (BATF3 À / À ) deficiency in host antigen-crosspresenting DC did not diminish the therapeutic action of intratumorally delivered wild-type mDC.Tbet. Interestingly, we observed that intratumoral delivery of mDC.Tbet (versus control mDC.Null) promoted the acute infiltration of NK cells and naive CD45RB þ T cells into the tumor microenvironment (TME) in association with elevated expression of NK-and T-cell-recruiting chemokines by mDC.Tbet. When taken together, our data support a paradigm for extranodal (cross)priming of therapeutic Type-1 immunity in the TME after intratumoral delivery of mDC.Tbet-based gene therapy.
INTRODUCTION
Dendritic cells (DC) are important antigen-presenting cells (APCs) that serve as qualitative and quantitative rheostats for developing T-cell responses in immune-competent hosts. [1] [2] [3] By carefully manipulating the conditions under which DC acquire, process and crosspresent antigens, the resulting cognate T-cell-mediated immunity may be modulated with regard to its magnitude, functional polarity and effector/memory status. 4, 5 When taken in the context of intrinsic or therapeutically induced immunity, DC can profoundly impact T-cell-mediated protection versus pathogenesis in the setting of infectious disease, autoimmunity or cancer. 6, 7 In the cancer setting, Type-1 CD8 þ T-cell (aka Tc1) responses have been most commonly associated with endogenous host protection or therapeutic benefit to immunotherapy. [8] [9] [10] [11] The ability to generate Type-1-polarized immunity has in turn been shown to depend on intrinsic expression of the transactivator protein T-bet (aka TBX21) by T-cell responders, and also perhaps more intriguingly, by DCs. 12 We have recently reported that DC transduced to express high levels of ectopic T-bet (DC.Tbet) are superior activators of Type-1 CD8 þ T cells from naive T-cell precursors in human in vitro experiments, 13 and that when injected directly into established CMS4 sarcoma lesions in Balb/c (H-2 d ) mice, the protective immunity results. 14 It remains unclear as to how DC.Tbet promote superior protective immunity, particularly in vivo. Using a subcutaneous MCA205 sarcoma model in C57BL/6 recipients and a range of informative syngenic (H-2 b ) mutant strains of mice serving as sources of mDC.Tbet cell for injection or as model hosts, we observed that intratumoral delivery of mDC.Tbet promotes the rapid recruitment and (cross)priming of polarized Type-1 natural killer (NK) and CD8 þ T-cell-mediated immunity within the tumor microenvironment (TME) that protects against tumor progression. These events were associated with a differential chemokine profile produced by injected DC.Tbet versus control DC, with the subsequent Type-1 polarization of CD8 þ T effector cells proving to be independent of mDC.Tbet production of interleukin (IL)-12 family member cytokines or interferon (IFN)-g. Overall, our data support a model in which the injected mDC.Tbet serve as dominant drivers for the extranodal (cross)priming of therapeutic immunity within the TME.
MATERIALS AND METHODS Mice
Female 6-to 8-week-old wild-type C57BL/6 (H-2 b ) mice, as well as IL-12p35 À / À , IL-12p40 À / À , IFN-g À / À , b2M À / À and CCR7 À / À mice (all on the B6 background) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Female CD11c-DTR (H-2 b ) conditional DC-deficient mice were kindly provided by Dr Louis Falo (University of Pittsburgh, Pittsburgh, PA, USA). Female BATF3 À / À mice deficient in crosspresenting DC were generated from 129-Batf3 À / À mice kindly provided by Dr Ken Murphy (Washington University-St Louis, St Louis, MO, USA) after backcrossing with C57BL/6 mice for five generations. Tbet-ZsGreen reporter mice were kindly provided under an MTA by Dr Jinfang Zhu (NIH/NIAID) via the NIAID repository maintained at Taconic (Hudson, NY, USA). All animals were handled under aseptic conditions as per an Institutional Animal Care and Use Committee (IACUC)-approved protocol and in accordance with recommendations for the proper care and use of laboratory animals.
Cell lines and culture
The MCA205 sarcoma (H-2 b ) cell line was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA), was free of Mycoplasma contamination and was maintained in complete medium (CM: RPMI-1640 media supplemented with 10% heat-inactivated fetal bovine serum, 100 mg ml À 1 streptomycin, 100 U ml À 1 penicillin and 10 mmol l À 1 L-glutamine, all reagents were purchased from Invitrogen, Carlsbad, CA, USA) at 5% CO 2 tension in a 37 1C humidified incubator.
Generation of bone marrow-derived DC and transduction with adenoviral vectors in vitro
DCs were generated from the tibias/femurs of mice, and infected with recombinant adenovirus (either empty, control Ad.c5 to produce mDC.Null or Ad.mT-bet to produce mDC.Tbet) at a multiplicity of infection of 250 for 48 h, as described previously. 14 Intracellular staining and flow cytometry was used to document expression of mTbet in Ad-infected DC (mDC.Tbet) as reported previously. 14 
Therapy model
Recipient wild-type, mutant or transgenic (H-2 b ) mice received subcutaneous injections of 5 Â 10 5 MCA205 sarcoma cells in the right flank on day 0. On day 7 or 8, after tumor inoculation as indicated, mice were randomized into treatment cohorts of five mice each exhibiting comparable mean tumor sizes (i.e. approximately 40 mm 2 ). Control DC (mDC.Null) or mDC.Tbet (10 6 ) developed from wild-type C57BL/6 or syngenic mutant mice were then injected intratumorally in a total volume of 50 ml (in phosphate-buffered saline) on days 7-8 after tumor inoculation and again 1 week later. Mean tumor size (±s.d.) was then assessed every 3-4 days and recorded in mm 2 by determining the product of the largest orthogonal diameters measured by vernier calipers. Mice were euthanized when tumors became ulcerated or if they reached a size of 400 mm 2 , in accordance with IACUC guidelines.
In vivo depletion of CD8 þ T cells, NK cells and CD11c þ DCs
In selected experiments as indicated, mice were injected intraperitoneally with 100-mg anti-CD8 mAb3-6.7 (ATCC) or 25-ml anti-asialoGM1 pAb (anti-asGM1; WAKO, Osaka, Japan) on days 6, 13 and 20 after tumor inoculation.
In some experiments, anti-asGM1 antibody (Ab) was administered on days 13 and 20 after tumor inoculation. To deplete CD11c þ DC from CD11c-DTR mice, diphtheria toxin (DT; Sigma-Aldrich, St Louis, MO, USA) was provided intraperitoneally at a dose of 4 mg DT per kg beginning on day 6 after tumor inoculation, as described previously. 15 Specific cell depletion was X95% effective in vivo based on flow cytometry analysis of peripheral blood monuclear cells obtained by tail venipuncture from treated mice 24-48 h after Ab or DT administration (data not shown).
Evaluation of CD8 þ T-cell responses against MCA205 tumor cells ex vivo
For in vitro stimulation cultures, spleens were harvested from two mice per cohort at various indicated time points after the intratumoral injection of phosphate-buffered saline, mDC.Null or mDC.Tbet. Splenic CD8 þ T cells (4 Â 10 5 ) were isolated using specific magnetic bead cell sorting (Miltenyi Biotec, Auburn, CA, USA), cultured in the absence or presence of irradiated (100 Gy) MCA205 cells (4 Â 10 4 cells per well) for 2 days in 96-well flatbottom plates in a humidified incubator at 37 o C and 5% CO 2 . Cell-free supernatants were then harvested and stored at À 80 o C before analysis using cytokine-specific OptEIA ELISA sets (BD Biosciences, San Diego, CA, USA) according to the manufacturer's instructions. Triplicate determinations were used in all instances, with data reported as the mean ± s.d.
Imaging of tumor tissues
Tumor samples were prepared and sectioned as reported previously. 14 Briefly, tumor tissues were harvested and fixed in 2% paraformaldehyde (Sigma-Aldrich) at 4 1C for 1 h, and then cryoprotected in 30% sucrose for 24 h. Tumor tissues were then frozen in liquid nitrogen and 6-mm cryosections prepared. For the analysis of T-cell subsets, sections were first stained with purified rat anti-mouse CD8a or purified rat anti-mouse CD4 (both from BD Pharmingen, San Diego, CA, USA) mAbs for 1 h. After washing, sections were stained with phycoerythrin-conjugated goat antirat secondary Ab (Jackson ImmunoResearch, West Grove, PA, USA). To detect NK cells and naive leukocytes, tissue sections were first stained with goat anti-mouse NKp46 Ab (R&D Systems, Minneapolis, MN, USA), followed by Cy3-conjugated donkey anti-goat pAb (Invitrogen). To detect naive leukocytes, tissue sections were stained with Cy5-conjugated rat antimouse CD45RB Ab (Abcam, Cambridge, MA, USA). Cell nuclei were then stained with 4 0 ,6-diamidino-2-phenylindole as described previously. 14 After washing, sections were then covered in Gelvatol (Monsanto, St Louis, MO, USA) and a coverslip was applied. Slide images were acquired using an Olympus 500 scanning confocal microscope (Olympus America, Center Valley, PA). The positively stained cells were quantified by analyzing the images at a final magnification of Â 20. The number of cells in sections with a given fluorescence phenotype was quantitated using Metamorph Imaging software (Molecular Devices, Sunnyvale, CA, USA).
RNA purification and polymerase chain reaction array analyses
Total RNA was isolated from mDC.Tbet and mDC.Null using Trizol reagents (Invitrogen, Carlsbad, CA). Total RNA was further purified using the RNeasy Plus Micro Kit (Qiagen, Germantown, MD) including the gDNA Eliminator spin column. The purity and quantity of the total RNA was assessed using Nanodrop ND-1000 (CelBio SpA, Milan, Italy). Total RNA (1 mg) was reversed transcribed into cDNA using the RT2 First Strand Kit (Qiagen), and the cDNA was added to RT2 SYBR Green ROXt qPCR Mastermix (Qiagen) and used for quantitative polymerase chain reaction using the RT2 Profiler PCR Array (96-well) for Mouse Chemokines and Receptors (Qiagen), all according to the manufacturer's instructions. Reactions were performed on a StepOnePlusTM Real-Time PCR thermocycler (Applied Biosystems, Bedford, MA) using the recommended cycling conditions. All mRNA expression levels were normalized to the expression of control glyceraldehyde 3-phosphate dehydrogenase mRNA.
Statistical analysis
Comparisons between groups were performed using a two-tailed Student's t-test or one-way analysis of variance (ANOVA) with post hoc analysis, as indicated. All data were analyzed using the SigmaStat software, version 3.5 (Systat Software, Chicago, IL, USA). Differences with a P-value o0.05 were considered as significant.
RESULTS
Therapeutic benefits of intratumoral delivery of mDC.Tbet are T-cell-and NK cell-dependent To assess the requirement for both innate and adaptive immunity in a successful therapeutic response to intratumoral mDC.Tbetbased treatment (provided on days 7 and 14 after tumor inoculation. MCA205 sarcoma), we used wild-type C57BL/6 or syngenic RAG1 À / À mice as hosts, without or with cotreatment of anti-asialoGM1 pAb or anti-CD8 mAb to depleted NK cells and CD8 þ T cells, respectively. We observed that intratumoral delivery of mDC.Tbet, but not control mDC.Null, slowed MCA205 tumor growth in wild-type C57Bl/6 mice ( Figure 1a ) but not B and T cell-deficient RAG1 À / À mice (Figure 1b ). Selective depletion of either CD8 þ T cells or NK cells (beginning on day 6 after tumor inoculation) also completely ablated protection against tumor growth afforded by intratumoral delivery of mDC.Tbet (Figures 1c and d) . Interestingly, even late depletion of NK cells (beginning on day 13 after tumor inoculation) resulted in a blunting of antitumor protection, suggesting the continued importance of NK function in the 'booster' phase of mDC.Tbet-based intratumoral therapy ( Figure 1d ).
Intratumoral delivery of T-bet gene transduced DC (DC.mTbet) generated from wild-type or IL-12p35 À / À , IL-12p40 À / À or IFN-g À / À mice provide similar therapeutic benefit against MCA205 sarcomas We have previously reported that human DC engineered to express ectopic Tbet (i.e. hDC.Tbet) promote superior Type-1 T-cell polarization in vitro via a mechanism that is poorly antagonized by neutralizing anti-IL-12 or anti-IFN-g antibodies. 13 However, in contrast to hDC.Tbet that are poor cytokine (including IL-12p70 and IFN-g) secretors when compared with their untransfected counterparts, 13 mDC.Tbet actually produce significantly more IL-12p70 than control DC, 14 which could underlie their improved therapeutic potency in tumor-bearing mice. To address definitively the role of intrinsic IL-12p70 and IFN-g production from mDC.Tbet in their therapeutic efficacy, we generated control DC (DC.Null) and DC.Tbet from the bone marrow of wild-type C57BL/6 mice or IL-12p35 À / À , IL-12p40 À / À or IFN-g À / À mice (on a C57BL/6 background), and injected these cells directly into subcutaneous MCA205 sarcomas that had been established for 7 days in C57BL/6 mice. An identical treatment was provided again 1 week later (i.e. on day 14 after tumor injection). As shown in Figure 2 , untreated MCA205-mice or tumor-bearing mice treated with control DC (regardless of their source) displayed indistinguishable progressive tumor growth. In contrast, therapies integrating intratumoral delivery of wild-type DC.Tbet or DC.Tbet developed from wild-type C57BL/6 mice or IL-12p35 À / À , IL-12p40 À / À (Figure 2a ) or IFN-g À / À (Figure 2b ) mice resulted in similarly prolonged suppression of tumor growth. These data suggest that (optimal) therapeutic efficacy of this approach is not dependent on intrinsic production of IL-12 family member cytokines (i.e. IL-12p70, IL-23 or IL-35 16 ), or IFN-g by mDC.Tbet.
Intratumoral delivery of DC.Tbet generated from b 2 M À / À mice provides an initial wild-type level of therapeutic protection that later becomes suboptimal, which correlates with antitumor CD8 þ T-cell responsiveness in treated mice Our previous work suggested that the improved ability of DC.Tbet to elicit protective Type-1 CD8 þ T-cell responses required the intimate contact or close proximity of these two cell populations during the antigen crosspresentation process. 13, 14 To investigate the requirement of major histocompatibility complex (MHC) class I/peptide presentation by injected mDC.Tbet in the therapeutic benefits associated with this cellular therapy, we delivered control or mDC.Tbet generated from wild-type versus b2M À / À mice into subcutaneous MCA205 tumors on days 7 and 14 after tumor inoculation and analyzed tumor growth and antitumor CD8 þ T-cell function over time. We observed that treatment with mDC.Tbet developed from b2M À / À (i.e. mDC.Tbet (b2M À / À )) or wild-type C57BL/6 (i.e. mDC.Tbet (WT)) mice provided a comparable degree of protection against tumor growth through days 16-19 after tumor inoculation, at which time tumors in the mDC.Tbet (b2M À / À )-treated cohort re-established accelerated growth kinetics versus tumors in mice treated with mDC.Tbet (WT) cells ( Figure 3a ). An analysis of splenic CD8 þ T cells harvested from the treated animals on days 18 and 34 revealed that although T-cell production of IFN-g in response to in vitro stimulation with MCA205 tumor cells was elevated to a comparable degree in the mDC.Tbet (WT)-and mDC.Tbet (b2M À / À )treated cohorts on day 18, only the mice receiving mDC.Tbet (WT) cells exhibited boosted antitumor Tc1 responses on day 34 of the study (Figure 3b ). Indeed, anti-MCA205 responses among CD8 þ Figure 1 . Intratumoral delivery of mDC.Tbet into established subcutaneous MCA205 sarcoma slows tumor growth via a mechanism involving innate and adaptive immunity. Control DC (mDC.Null) or mDC.Tbet were generated from the bone marrow of wild-type C57BL/6 mice as outlined in Materials and methods. Phosphatebuffered saline or 10 6 mDC (as indicated) were then injected directly into subcutaneous MCA205 sarcomas established in syngenic wildtype (a) or RAG1 À / À (b) mice on days 7 and 14 after tumor inoculation. The experiment described in a was then repeated, with cohorts of mDC.Tbet-treated mice also receiving intraperitoneal injections of depleting anti-CD8 (c) or anti-NK (i.e. anti-asGM1 on days 6, 13 and 20; or on days13 and 20; d) antibodies. In all cases, tumor growth was monitored every 3-4 days and is reported in mm 2 (mean±s.d. of five animals per group). Data are representative of three independent experiments performed. *Po0.05 versus phosphate-buffered saline or mDC.Null on the indicated days of analysis (ANOVA). Figure 2 . Delivery of mDC.Tbet into tumors mediates antitumor activity independent of the intrinsic capacity of the injected DCs to produce IL-12 family member cytokines or IFN-g. Control mDC.Null or mDC.Tbet were generated from the bone marrow of C57BL/6 wild-type (WT) mice or from syngenic IL-12p35 À / À (p35 À / À ) or IL-12p40 À / À (p40 À / À ) mice (a) or IFN-g À / À (IFN À / À ) mice (b). The various DC (10 6 ) were then injected directly into subcutaneous MCA205 sarcomas established in wild-type C57BL/6 mice on days 7 and 14 after tumor inoculation. Tumor growth was then monitored every 3-4 days and is reported in mm 2 (mean ± s.d. of five animals per group). Data are representative of three independent experiments performed in each case. *Po0.05 for mDC.Tbet (WT), mDC.Tbet (p35 À / À ), mDC.Tbet (p40 À / À ) and mDC.Tbet (IFN À / À ) versus control mDC.Null-treated animals on the indicated days of analysis (ANOVA).
T cells harvested from mice treated with mDC.Tbet (b2M À / À ) had dramatically eroded to essentially control levels by day 34. These data tentatively suggest that MHC class I expression by the injected mDC.Tbet may not be required for the initial induction of antitumor CD8 þ T cells (despite its expected requirement for direct crosspresentation of antigen to T cells by injected DC 17 ), but that it is likely needed for the sustained function and optimal therapeutic action of T effector cells in treated mice on or after day 16 of treatment.
To test this directly, we performed a 'crisscross' study design in which MCA205 tumor-bearing mice first received intratumoral delivery of mDC.Tbet (WT) or mDC.Tbet (b2M À / À ) on day 7 after tumor inoculation, followed by either population of mDC.Tbet cells 1 week later. Control therapy consisted of intratumoral delivered DC.Null on both days 7 and 14. As depicted in Figure 3c , all therapies using mDC.Tbet (from either WT or b2M À / À mice) exhibited indistinguishable antitumor protection benefits through day 17 after MCA205 inoculation. Thereafter, the extended therapeutic efficacy was greatest in mice receiving two injections of mDC.Tbet (WT), followed by mice receiving mDC.Tbet (WT) on day 7, then mDC.Tbet (b2M À / À ) on day 14, followed by mice receiving mDC.Tbet (b2M À / À ) on day 7, regardless of which secondary treatment was applied. These results suggest that durability of protective immunity (X day 17) activated by mDC.Tbet-based treatment is determined by whether the injected mDC.Tbet express MHC class I at the time of priming (with the most robust responses involving day 7 delivery mDC.Tbet (WT) cells). Therapies initiated with mDC.Tbet (b2M À / À ) cells atrophy over time and are not salvaged by secondary treatment with DC.Tbet (WT) cells. Furthermore, therapy initiated with DC.Tbet (WT) cells deteriorates more quickly if DC.Tbet (b2M À / À ) cells rather than DC.Tbet (WT) cells are delivered on day 14 after inoculation.
Therapeutic benefits provided by intratumoral delivery of mDC.Tbet is independent of host CD11c þ and CD103 þ CD11b À DC populations and does not require CCR7-dependent mDC.Tbet trafficking to secondary lymphoid tissues Our therapeutic results using mDC.Tbet (b2M À / À ) suggested the enhanced early priming of anti-MCA205 CD8 þ T cells in a system where the injected APC were conceptualy not competent in crosspriming capacity. This suggested a possible paradigm in which the injected mDC.Tbet might directly or indirectly (via NK cell crosslicensing 18, 19 ) activate host DC populations known to crossprime effectively T cells, such as CD8a þ CD11c þ DC or CD103 þ CD11b neg DC, [20] [21] [22] [23] in the TME or tumor-draining lymph node. To address this issue, mDC.Tbet were injected into subcutaneous MCA205 tumors established in BATF3 À / À mice (deficient in CD8a þ CD11c þ and CD103 þ CD11b neg DC 23 ) as a therapy on days 7 and 14 after tumor inoculation. In this model, mDC.Tbet-based treatment provided substantial and sustained antitumor protection (Figure 4a ), suggesting that these important host crosspriming DC populations are not critically required in the therapeutic response. As additional host CD11c þ CD8a neg DC populations might also participate in the therapeutic crosspriming of adaptive immunity in our model, we also delivered mDC.Tbet (WT) into MCA205 tumors established in CD11c-DTR mice to which DT could then be administered to deplete selectively CD11c þ host DC in vivo. As shown in Figure 4b , we observed that this maneuver had no detrimental impact on the protection of tumor-bearing mice treated with mDC.Tbet (WT), suggesting that host CD11c þ DC did not have a dominant role in the antitumor benefits associated with this immunotherapy.
Expression of CCR7 by crosspresenting DC is required for their migration from peripheral tissue sites to secondary lymphoid organs in response to ligand chemokines, CCL19 and CCL21. [24] [25] [26] [27] To address the requirement of intratumorally-delivered mDC.Tbet to migrate to tumor-draining lymph nodes to crossprime therapeutic T cells that provide protection against tumor progression, we generated these APC from wild-type or CCR7 À / À mice and injected them into MCA205 sarcomas established in wild-type C57BL/6 mice on days 7 and 14 after tumor inoculation. We observed that intratumoral therapy incorporating mDC.Tbet (CCR7 À / À ) provided a level of antitumor protection that was indistinguishable from that seen in MCA205-bearing mice treated with wild-type mDC.Tbet (Figure 4c ). This suggests that the therapeutic action mediated by intratumoral administration of mDC.Tbet likely occurs principally in the TME, with minimal required involvement of secondary lymphoid tissues.
Intratumorally delivered mDC.Tbet promote superior early recruitment/activation of Type-1 CD8 þ T cells and NK cells within the therapeutic TME in association with enhanced production of chemokines Several recent publications indicate that the vast majority of DC delivered into a tumor lesion in vivo fail to migrate out of the tumor lesion, 14, 28, 29 suggesting that their predominant therapeutic impact likely occurs within the TME. Although somewhat unconventional, the crosspriming of naive, antigen-specific T-cell responses can occur in extranodal tissue sites including bone Figure 3 . Intratumoral therapy with DC.Tbet developed from b2M À / À mice promotes a transient phase of antitumor benefit that ultimately fails, leading to the re-establishment of progressive tumor growth which cannot be 'rescued' by booster injections of mDC.Tbet (WT). (a) Control mDC.Null or mDC.Tbet were generated from the bone marrow of wild-type C57BL/6 mice (WT) or syngenic (H-2 b ) mice deficient in MHC class I expression (based on b 2 mdeficiency; b2M À / À ) as outlined in Materials and methods, and (10 6 ) of a given APC population injected directly into established subcutaneous MCA205 sarcomas in C57BL/6 mice on days 7 and 14 after tumor inoculation. Tumor growth was then monitored every 3-4 days and the tumor size reported in mm 2 (mean ± s.d. of five animals per group). In b, on day 18 or 34 after tumor inoculation (i.e. 4 or 20 days after the second DC injection, respectively), CD8 þ splenocytes were (MACS) isolated for functional analysis. CD8 þ T cells were cocultured in the absence or presence of irradiated MCA205 tumor cells at a 10:1 (T cell-to-tumor cell ratio) for 48 h, at which time cell-free supernatants were analyzed for IFN-g content by ELISA. Reported data have deducted values obtained for T-cellonly cultures. *Po0.05 (t-test) versus mDC.Null (WT); **Po0.05 versus all other cohorts (ANOVA). In c, a study design was repeated, with the exception that the second intratumoral injection of mDC.Tbet (day 14 after tumor inoculation) was either mDC.Tbet (WT) or mDC.Tbet (b2M À / À ). Data are representative of three independent experiments performed. *Po0.05 versus mDC.Null (WT) (t-test); **Po0.05 versus the DC.Tbet (WT)-DC.Tbet (WT) treated cohort (ANOVA). Panel data are representative of three independent experiments performed.
DC.Tbet gene therapy for cancer L Chen et al marrow, skin, lungs and even tumors. 27, [30] [31] [32] To evaluate whether early recruitment and activation of Type-1 T-cell and NK cell responses were occurring in the MCA205 microenvironment, we established tumors subcutaneously in syngenic (H-2 b ) Tbet-ZsGreen reporter mice that encode fluorescent ZsGreen protein driven off a genomic Tbet/TBX21 promoter. 33 Tumor-bearing mice were left untreated, or they were treated with intratumorally delivered mDC.Null or mDC.Tbet generated from wild-type C57BL/ 6 mice. After 2 days, tumors were harvested and tissue sections evaluated by fluorescence microscopy for Type-1-polarized CD4 þ T-cell, CD8 þ T-cell and NK (NKp46 þ ) cell responses based on the conditional (ZsGreen) fluorescence of these lymphoid subsets. 33 As shown in Figures 5a and b , within a 48-h period of administering mDC.Tbet (versus control mDC.Null) into tumors, a dramatic increase in Type-1 (ZsGreen þ ) NK cells, CD4 þ T cell and CD8 þ T cells was observed within the TME. Many of these T-cell recruits appeared to represent 'naive' or newly-primed cell populations, as fluorescence microscopy revealed a preponderance of CD45RB þ CD3 þ TIL in mDC.Tbet (WT) but not controltreated mice (Figure 5c and Table 1) , with 60% of CD45RB þ CD3 þ T cells coexpressing ZsGreen protein ( Table 1) . As such acute recruitment and priming/activation of T cells and NK cells into/within the TME would be most simply explained based on chemokines elaborated from intratumorally delivered mDC.Tbet, we performed chemokine gene expression profiling of mDC.Tbet (WT) versus mDC.Null (WT). As shown in Figure 6 , mDC.Tbet intrinsically expressed elevated transcript levels (X1.2-fold) for the chemokines CCL1, CCL4, CCL6, CCL8, CCL12, CCL17, CCL28, CXCL12 and CXCL15 when compared with control DC.
DISCUSSION
The major finding of this work is that DC engineered to express high levels of the Type-1 transactivator protein T-bet (aka TBX21) and injected into established MCA205 sarcomas promote therapeutic immunity via an unconventional mechanism in an unconventional location in tumor-bearing mice. Our data suggest that mDC.Tbet slow tumor growth via an immune-mediated mechanism involving the activation of effector CD8 þ T cells and NK cells, that the (acute) crosspriming of antitumor CD8 þ T cells does not qualitatively require intrinsic expression of MHC class I molecules on the cell surface of injected DC, nor does it involve the critical participation of host (CD8a þ CD11c þ or CD103 þ CD11b neg ) DC populations classically known to promote the robust crosspriming of T cells. Furthermore, the injected DC need not have the intrinsic capacity to produce IL-12 family cytokines (i.e. IL-12, IL-23, IL-35) or IFN-g, or to migrate to TuDLN based on responsiveness to CCR7 ligand chemokines. Interestingly, the injection of mDC.Tbet directly into the tumor lesion appears to support the rapid recruitment and activation of Type-1 (Tbet þ ) T cells and NK cells within the TME, allowing for extranodal priming of protective immunity in this system. Our hypothetical model of this paradigm (Figure 7) does not preclude additional (more conventional) crosspriming of protective CD8 þ T cells in TuDLN; however, the treatment-associated benefits of effector cells elicited in this manner appear modest in comparison with those promoted within the TME as a consequence of mDC.Tbet administration.
Naive T cells (including recent thymic emigrants) are believed to circulate through non-lymphoid tissues as part of their normal migratory pathway, and can also be recruited or retained in peripheral (non-nodal) sites based on locoregional production of chemokine ligands for CCR7 (i.e. CCL19, CCL21), CCR9 (i.e. CCL25) and CXCR4 (CXCL12/SDF-1a refs [34] [35] [36] [37] . Under such (unconventional) conditions, extranodal priming of naive T cells has been reported to occur in a range of tissues including the bone marrow, liver, lungs, skin and even tumors. 27, 30, 31, 36, 38, 39 Notably, the (cross)priming of protective T cells can be leveraged by the selective production of recruiting chemokines as a consequence of certain gene therapies applied to the TME. 32, 40, 41 NK cells, which can mediate tumoricidal activity as well as the 'licensing' of DC for improved T-cell crosspriming capacity, 42, 43 may also be recruited into extranodal tissue sites based on DC-produced chemokines such as CCL1/I-309, CCL2/MCP-1, CCL4/MIP-1, CCL5/RANTES, CCL7/TARC, CCL22/MDC, CXCL8/IL-8 or CXCL10/IP-10. [44] [45] [46] Also of significant interest, a recent report by Messina et al. 47 suggests that a 12 chemokine (i.e. CCL2-CCL5, CCL8, CCL18-CCL21, CXCL9-CXCL11 and CXCL13) gene signature may be associated with the presence of lymph node-like stuctures within the TME of advanced-stage melanomas and be predictive of patient responsiveness to immunotherapy and overall survival. In this Figure 4 . Host crosspresenting DC and the ability of intratumorally delivered mDC.Tbet (WT) to traffick to tumor-draining lymph nodes are not required for the antitumor efficacy of this therapeutic approach. MCA205 tumors were established subcutaneous in the flanks of syngenic BATF3 À / À (a) or CD11c-DTR (b) mice. On days 7 and 14 after tumor inoculation, 10 6 mDC.Null (WT) or mDC.Tbet (WT) were injected intratumorally, with tumor growth monitored every 3-4 days and the tumor size reported in mm 2 (mean ± s.d. of five animals per group). In b, host CD11c þ DC were depleted in vivo by intraperitoneal administration of DT as described in Materials and methods section. In c, established subcutaneous MCA205 tumors in wild-type C57BL/6 mice were treated with days 7 and 4 intratumoral injections of 10 6 mDC.Null or mDC.Tbet generated from either C57BL/6 WT mice or syngenic CCR7 À / À mice and tumor size monitored longitudinally. Data are representative of three independent experiments performed. *Po0.05 for mDC.Tbet (WT or CCR7 À / À ) versus mDC.Null (WT) (ANOVA) at the indicated time points; not significant difference (NS) in b for mDC.Tbet (WT) versus mDC.Tbet (WT) þ DT or in c for mDC.Tbet (CCR7 À / À ) versus mDC.Tbet (WT) (ANOVA). Panel data are representative of three independent experiments performed.
regard, our transcriptional profiling of murine DC.Tbet suggest the differential ability of DC.Tbet versus control DC to produce NK (CCL1, CCL4, CCL6, CCL8, CXCL12) and naive T (CCL4, CCL17, CXCL12) cell-recruiting chemokines (Figure 6and refs 35,44,48-53 ) in support of extranodal induction of protective immunity in the TME. Of these, CCL1 (which along with CCL17 promotes extended cognate interaction of naive T cells with DC and consequent Type-1 T effector cell polarization 54 ) and CCL4 were also overexpressed at the transcript level by human DC.Tbet versus control human DC.Null ( Supplementary Table SI ). Future experiments using neutralizing antibodies or small interfering RNA knockdown of these chemokines in injected DC.Tbet may allow us to determine the intrinsic importance of one or more of these soluble recruiting molecules in the antitumor efficacy of our DC-based gene therapy and to discern whether this treatment approach supports the establishment of lymph node-like structures in the TME over time in cases of stabilized disease.
Once recruited into the TME as a consequence of intratumorally delivered mDC.Tbet, optimal crosspriming of antitumor CD8 þ T cells is likely mediated predominantly by the injected mDC.Tbet that have acquired, processed and presented tumor-associated antigens in their MHC class I complexes in situ, based on results obtained in our studies using therapeutic mDC.Tbet generated from b2M À / À mice. However, even though mDC.Tbet (b2M À / À ) Figure 5 . Early recruitment and activation of Type-1 T cells and NK cells in the TME after intratumoral delivery of mDC.Tbet versus mDC.Null. In a, MCA205 tumors were established subcutaneous in the flanks of syngenic (H-2 b ) Tbet-ZsGreen reporter mice. On day 7 after tumor inoculation, 10 6 mDC.Null (WT) or mDC.Tbet (WT) were injected intratumorally. After 2 days, (i.e. days 9 after tumor inoculation), animals were euthanized and tumor isolated for fluorescence microscopy analysis of infiltrating CD4 þ T cells, CD8 þ T cells and NKp46 þ NK cells as described in Materials and methods. In situ activated Type-1 host cells express ZsGreen protein as a consequence of transcription driven off the mTbet promoter. In b, quantitation of events in a images was performed using the Metamorph software and is reported as the mean ± s.d. of 10 high-power fields per specimen. In c, tumor sections from a were analyzed by fluorescence confocal microscopy for the presence of 'naïve' T cells based on coexpression of CD45RB (blue) and CD3 (red), with intrinsic Tbet-ZsGreen expression indicated in green. White arrows indicate CD45RB þ CD3 þ T cells (red/blue overlay yielding a fuschia pseudocolor). Quantitation of fluorescence images was performed using Metamorph software and is reported in Table 1 . Panel data are representative of three independent experiments performed. Abbreviations: HPF, high-power field; WT, wild type. Fluorescence confocal microscopy images obtained in Figure 5c were analyzed using Metamorph software as described in Materials and methods, with data as the mean±s.d. of 10 high-power field per specimen. *Po0.05 for mDC.Tbet (WT) versus mDC.Null (WT) (t-test). Data are representative of those obtained in three independent experiments performed. Figure 6 . Differential expression of chemokine transcripts by mDC.Tbet versus control mDC.Null. mDC.Tbet (WT) and mDC.null (WT) were prepared as outlined in Materials and methods and allowed to incubate for an additional 48h after infection with recombinant adenovirus. After extracting mRNA from both cell populations, chemokine/chemokine receptor transcripts were then analyzed using a commercial real-time reverse transcriptionpolymerase chain reaction array as described in Materials and methods. The ratio of transcript levels for a given gene product among total tumor mRNA isolated from mDC.Tbet versus mDC.Null is reported. support the induction of some degree of protective CD8 þ T-cellmediated immunity, the resultant antitumor protection associated with this immunity appears to be of a lower quality/durability than that developed in therapies using mDC.Tbet (WT). Such lower therapeutic efficiency/efficacy linked to administration of mDC.Tbet (b2M À / À ) could be the result of one or more limitations, including but not limited to: (i) the provision of suboptimal activation signals by mDC.Tbet (b2M À / À ) to cognate T-cell responders based on the limited crosspresenting ability of these MHC class I-deficient APC; (ii) the modest ability of these APC to crossprime/boost protective CD8 þ T cells in secondary lymphoid organs; and/or (iii) premature demise or NK-mediated eradication of these MHC class-deficient APCs in vivo, thereby limiting the functional duration of adaptive immune stimulation. 55 With regard to the first point, it is conceivable that despite a genetic deficiency in b2M expression, that mDC.Tbet (b2M À / À ) may acquire a limited capacity to activate tumor-specific CD8 þ T cells in the TME via the pirating of tumor membrane components or the uptake of tumor-derived exosomes, both of which contain MHC class I/peptide complexes. 56 Alternatively or additionally, soluble b2M (found in mg ml À 1 quantities in the serum 57 ) may be taken up along with tumor antigens by mDC.Tbet (b2M À / À ), allowing for the stabilization of sufficient MHC I/tumor peptide complexes 58 on the injected DC cell surface to permit at least a limited degree of specific T-cell induction in the TME. It is also conceivable that mDC.Tbet ± NK cells condition the TME to allow for the priming/activation of CD8 þ T cells by CD11c neg tumorassociated macrophages or even tumor cells themselves, although these would likely be considered as comparatively inefficient APC for this purpose. 59 That extranodal (cross)priming of T-cell responses in peripheral tissues versus secondary lymphoid organs may yield a responding T-cell repertoire that differs in overall magnitude or quality has been previously suggested in infectious disease models in CCR7 À / À mice. 27 When challenged with aerosolized live mycobacteria, CCR7 À / À animals crossprime-specific T cells in the lungs rather than the mediastinal lymph nodes. 27 The resulting immunity protects against only low doses of bacterial rechallenge, in contrast to wild-type mice vaccinated in a similar manner, in which case the animals withstand far greater doses of bacterial challenge. 27 This paradigm could underlie the inability of antitumor T cells crossprimed by mDC.Tbet (b2M À / À ) to regulate the growth of MCA205 tumors after they reach a certain size (i.e. tumor load), resulting in lethal, progressive disease. Our data also suggest that the inherent quality (and antitumor efficacy) of antitumor CD8 þ T cells is dominantly imprinted at the time of first intratumoral delivery of mDC.Tbet, as a booster injection of mDC.Tbet (WT) did not dramatically reinforce the antitumor protection initiated by mDC.Tbet (b2M À / À ). This interpretation is further supported by our findings that within 2 days of intratumoral delivery of mDC.Tbet more than half of the enriched population of CD45RB þ CD3 þ TIL already expresses evidence of Type-1 Figure 7 . A hypothetical model for extranodal priming of therapeutic immunity in the TME after intratumoral delivery of mDC.Tbet. In this model, delivery of mDC.Tbet leads to the acute recruitment of NK cells and naive CD8 þ T cells, based on injected DC production of chemokines. Such recruitment into the TME fosters the crosspriming and polarization of antitumor CD8 þ T cells in a manner independent of IL-12 family member cytokine or IFN-g production by the injected mDC.Tbet cells. Optimal induction of protective immunity requires MHC class I expression by the injected DC based on our observations for the inferior quality/durability of protective CD8 þ T cells developed in therapies using intratumorally delivered DC.Tbet (b2M À / À ). Host DC populations do not have dominant roles in the therapeutic benefits associated with intratumoral delivery of mDC.Tbet. Activation of specific antitumor T cells in the tumor-draining lymph nodes is comparatively weak. The majority of extranodally primed CD8 þ T cells remain in the TME and is boosted/sustained by the second intratumoral injection of mDC.Tbet, although some peripheral (tumor-draining lymph nodes, spleen) expansion of the antitumor CD8 þ T-cell may also be therapeutically potentiated over time.
polarization based on ZsGreen reporter protein expression ( Figure 5c and Table 1 ).
The theoretical locoregional impact of 'booster' mDC.Tbet delivered intratumorally on day 14 after tumor inoculation on protective CD8 þ T cells resulting from the initial administration of mDC.Tbet into the TME may be extrapolated from previous studies in which genetically modified DCs were injected intratumorally in concert with the adoptive transfer of preactivated tumor antigen-specific CD8 þ T cells. [60] [61] [62] Thus, DC engineered to produce IFN-a enhanced recruitment of intravenously administered Type-1 antitumor CD8 þ T cells in a CXCL10/IP-10 chemokine-dependent manner. 60 Also in this light, several recent reports [61] [62] [63] are intriguing since intratumoral delivery of DC loaded with tumor antigens (versus unloaded DC) was observed to maximally enhance the accumulation and antitumor efficacy of adoptively transferred or vaccine-induced tumor antigen-specific CD8 þ T cells. This suggests that the crosspresentation of cognate antigen by injected mDC.Tbet (rather than or in addition to tumor cells themselves) to CD8 þ T cells in the TME may be critical for optimal and sustained antitumor T effector cell function in vivo. Booster intratumorally delivered mDC.Tbet would also be expected to intrinsically produce or promote the IFN-g-dependent (from Type-1 T cells and NK cells) elaboration of CXCR3 ligand chemokines, 14, 60 thereby reinforcing the recruitment and/ or sequestration of protective antitumor CD8 þ T cells into/within the TME and extending therapeutic benefit.
When taken together, our data support the ability of intratumorally delivered mDC.Tbet (WT) to recruit, prime and sustain superior Type-1 antitumor immunity within the TME. Intratumoral delivery of hDC.Tbet would be predicted to have translational merit in the context of vaccines and as a cotherapy with adoptive cellular therapy in patients with accessible (i.e. injectable) forms of solid cancer.
